Articles dans des revues avec comité de lecture (5)
  1. 1. Ravon, F., Berns, E., Lambert, I., Rens, C., Adnet, P.-Y., Kiass, M., Megalizzi, V., Delporte, C., Baulard, A., Mathys, V., Boarbi, S., Wauthoz, N., & Fontaine, V. (2025). Assessment of Innovative Dry Powders for Inhalation of a Synergistic Combination Against Mycobacterium tuberculosis in Infected Macrophages and Mice. Pharmaceutics, 17(6), 705. doi:10.3390/pharmaceutics17060705
  2. 2. Ravon, F., Menchi, E., Lambot, C., Al Kattar, S., Chraibi, S., Remmelink, M., Fontaine, V., & Wauthoz, N. (2022). In vitro and in vivo local tolerability of a synergistic anti‐tuberculosis drug combination intended for pulmonary delivery. Journal of applied toxicology, 1-14. doi:10.1002/jat.4381
  3. 3. Zeng, S., Soetaert, K., Ravon, F., Vandeput, M., Bald, D., Kauffmann, J.-M., Mathys, V., Wattiez, R., & Fontaine, V. (2019). Isoniazid Bactericidal Activity Involves Electron Transport Chain Perturbation. Antimicrobial agents and chemotherapy, 63(3). doi:10.1128/AAC.01841-18
  4. 4. Sharbati, S., Ravon, F., Einspanier, R., & Bruegge, J. Z. (2019). Mycobacterium smegmatis but not mycobacterium avium subsp. Hominissuis causes increased expression of the long non-coding rna meg3 in thp-1-derived human macrophages and associated decrease of tgf-β. Microorganisms, 7(3), 63. doi:10.3390/microorganisms7030063
  5. 5. Zeng, S., Soetaert, K., Ravon, F., Vandeput, M., Bald, D., Kauffmann, J.-M., Mathys, V., Wattiez, R., & Fontaine, V. (2019). Isoniazid bactericidal activity involves electron transport chain perturbation. Antimicrobial agents and chemotherapy, 63(3), 1-20.
    6.   Communications publiées lors de congrès ou colloques nationaux et internationaux (1)
  6. 1. Ravon, F., Menchi, E., Remmelink, M., Chraibi, S., Fontaine, V., & Wauthoz, N. (2022). In vitro and in vivo evaluations of the tolerance of a new and innovative anti-tuberculosis drug combination by inhalation. Abstracts from The Aerosol Society Drug Delivery to the Lungs 32. Vol. 35(35), A1-A20 (pp. 1-20) Drug Delivery to the Lungs(32: 8-10th December: Virtual). doi:10.1089/jamp.2022.ab01.abstracts
    7.   Participations à des congrès et colloques internationaux (1)
  7. 1. Ravon, F., Menchi, E., Remmelink, M., Chraibi, S., Fontaine, V., & Wauthoz, N. (2021). In vitro and in vivo evaluations of the tolerance of a new and innovative anti-tuberculosis drug combination by inhalation. Paper session presented at Drug Delivery to the Lung (32: 8-10th December 2021: Virtual).
    8.   Thèses et mémoires (1)
  8. 1. Ravon, F. (2024). In vitro and in vivo evaluations of an innovative drug combination for pulmonary administration against tuberculosis (Thèse doctorale non-publiée). Université libre de Bruxelles, Faculté de Pharmacie, Bruxelles.